Prevalence of Hepatitis C Virus Infection Among Prisoners in Iran: a Systematic Review and Meta-analysis

Overview

Journal Harm Reduct J

Publisher Biomed Central

Specialties Pharmacology
Psychiatry

Date 2018 May 10

PMID 29739400

Citations 23

Authors

Masoud Behzadifar

Hasan Abolghasem Gorji

Aziz Rezapour

Nicola Luigi Bragazzi

Affiliations

Soon will be listed here.

Abstract

Background: Hepatitis C virus (HCV) is one of the major public health problems both in developed and developing countries. Prison represents a high-risk environment for prisoners, in that it is characterized by high-risk behaviors such as injecting drug use (IDU), tattooing, unprotected sexual intercourses, or sharing syringes. The aim of this study was to quantitatively evaluate the prevalence of HCV among Iranian prisoners conducting a systematic review and meta-analysis.

Methods: We searched different scholarly databases including Embase, PubMed/MEDLINE, ISI/Web of Sciences, the Cochrane library, Scopus, CINAHL, and PsycINFO as well as Iranian bibliographic thesauri (namely, Barakatns, MagIran, and SID) up to December 2017. The Newcastle Ottawa Scale (NOS) was used to assess the quality of the studies included. HCV prevalence rate with its 95% confidence interval (CI) was estimated using the DerSimonian-Laird random-effects model, with Freeman-Tukey double arcsine transformation. Egger's regression test was used to evaluate publication bias.

Results: Finally, 17 articles were selected based on inclusion and exclusion criteria. Overall, 18,693 prisoners were tested. Based on the random-effects model, the prevalence of HCV among Iranian prisoners was 28% (CI 95% 21-36) with heterogeneity of I = 99.3% (p = 0.00). All studies used an ELISA test for the evaluation of HCV antibodies. The findings of this study showed that the highest prevalence rate (53%) was among prisoners who inject drugs.

Conclusion: The findings of our study showed that the prevalence of HCV among Iranian prisoners is dramatically high. Managing this issue in Iran's prisons requires careful attention to the availability of health facilities and instruments, such as screening, and harm reduction policies, such as giving sterile syringes and needles to prisoners. An integrated program of training for prisoners, prison personnel and medical staff is also needed to improve the level of health condition in prisons.

Citing Articles

Prevalence of hepatitis B, hepatitis C, and tuberculosis among people living with HIV in Iran: a systematic review and meta-analysis.

Mostafavi E, Ebrahimi B, Doosti-Irani A, Mirzazadeh A BMC Infect Dis. 2024; 24(1):777.

PMID: 39097724 PMC: 11297631. DOI: 10.1186/s12879-024-09676-4.

Seroepidemiological Investigation of Hepatitis B and C Prevalence and Associated Factors Among People in Custody at Zahedan Central Prison.

Metanat M, Almasi S, Sepehri Rad N, Tabatabaee S, Rezaei K Arch Iran Med. 2024; 27(6):298-304.

PMID: 38855799 PMC: 11264623. DOI: 10.34172/aim.23553.

Hepatitis B and hepatitis C virus infections and associated factors among prisoners in Gondar City, Northwest Ethiopia.

Tadesse K, Ayalew G, Million Y, Gelaw A PLoS One. 2024; 19(4):e0301973.

PMID: 38626232 PMC: 11020974. DOI: 10.1371/journal.pone.0301973.

Prevalence of Symptom-based Sexually Transmitted Infections and Related Factors among Incarcerated Men in Iran, 2013.

Shahesmaeili A, Shokoohi M, Tavakoli F, Rabiee M, Kamali K, Haghdoost A Med J Islam Repub Iran. 2022; 35:185.

PMID: 36042833 PMC: 9391771. DOI: 10.47176/mjiri.35.185.

Sociodemographic characteristics and HIV risk behaviors of native-born and displaced Syrian men and transgender women who have sex with men in Lebanon.

Orr L, Crawford F, Khoshnood K, Khouri D, Fouad F, Seal D AIDS Behav. 2022; 26(12):4004-4011.

PMID: 35672550 DOI: 10.1007/s10461-022-03726-1.

References

Keten D, Emin Ova M, Keten H, Keten A, Gulderen E, Tumer S . The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey. Jundishapur J Microbiol. 2016; 9(2):e31598. PMC: 4842253. DOI: 10.5812/jjm.31598. View

Stone J, Martin N, Hickman M, Hutchinson S, Aspinall E, Taylor A . Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017; 112(7):1302-1314. PMC: 5461206. DOI: 10.1111/add.13783. View

Ioannidis J, Patsopoulos N, Rothstein H . Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008; 336(7658):1413-5. PMC: 2432114. DOI: 10.1136/bmj.a117. View

Stanaway J, Flaxman A, Naghavi M, Fitzmaurice C, Vos T, Abubakar I . The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388(10049):1081-1088. PMC: 5100695. DOI: 10.1016/S0140-6736(16)30579-7. View

Fox R, Currie S, Evans J, Wright T, Tobler L, Phelps B . Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis. 2005; 41(2):177-86. DOI: 10.1086/430913. View

Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry J . Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000; 321(7253):78-82. PMC: 27426. DOI: 10.1136/bmj.321.7253.78. View

Shaheen M, Idrees M . Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol. 2015; 7(3):616-27. PMC: 4381185. DOI: 10.4254/wjh.v7.i3.616. View

Niriella M, Hapangama A, Luke H, Pathmeswaran A, Kuruppuarachchi K, de Silva H . Prevalence of hepatitis B and hepatitis C infections and their relationship to injectable drug use in a cohort of Sri Lankan prison inmates. Ceylon Med J. 2015; 60(1):18-20. DOI: 10.4038/cmj.v60i1.7288. View

Saberi Zafarghandi M, Jadidi M, Khalili N . Iran's Activities on Prevention, Treatment and Harm Reduction of Drug Abuse. Int J High Risk Behav Addict. 2016; 4(4):e22863. PMC: 4744908. DOI: 10.5812/ijhrba.22863. View

10.

Spaulding A, Seals R, McCallum V, Perez S, Brzozowski A, Steenland N . Prisoner survival inside and outside of the institution: implications for health-care planning. Am J Epidemiol. 2011; 173(5):479-87. PMC: 3044840. DOI: 10.1093/aje/kwq422. View

11.

Dolan K, Wirtz A, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner S . Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016; 388(10049):1089-1102. DOI: 10.1016/S0140-6736(16)30466-4. View

12.

Saiz de la Hoya P, Marco A, Garcia-Guerrero J, Rivera A . Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011; 30(7):857-62. DOI: 10.1007/s10096-011-1166-5. View

13.

Larney S, Kopinski H, Beckwith C, Zaller N, Des Jarlais D, Hagan H . Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013; 58(4):1215-24. PMC: 3723697. DOI: 10.1002/hep.26387. View

14.

Liao K, Lai S, Chang W, Hsu N . Screening for viral hepatitis among male non-drug-abuse prisoners. Scand J Gastroenterol. 2006; 41(8):969-73. DOI: 10.1080/00365520500535576. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

16.

Butler T, Kariminia A, Levy M, Kaldor J . Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol. 2005; 19(12):1119-22. DOI: 10.1007/s10654-004-1705-9. View

17.

Spaulding A, Sharma A, Messina L, Zlotorzynska M, Miller L, Binswanger I . A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health. 2015; 105(5):e51-7. PMC: 4386519. DOI: 10.2105/AJPH.2014.302546. View

18.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

19.

Brandolini M, Novati S, De Silvestri A, Tinelli C, Patruno S, Ranieri R . Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. BMC Public Health. 2013; 13:981. PMC: 3854608. DOI: 10.1186/1471-2458-13-981. View

20.

Fazel S, Baillargeon J . The health of prisoners. Lancet. 2010; 377(9769):956-65. DOI: 10.1016/S0140-6736(10)61053-7. View